Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares were down 2.1% during mid-day trading on Thursday . The company traded as low as C$7.67 and last traded at C$7.82. Approximately 134,964 shares changed hands during trading, an increase of 1,721% from the average daily volume of 7,410 shares. The stock had previously closed at C$7.99.
Eupraxia Pharmaceuticals Price Performance
The firm’s 50-day moving average is C$8.27 and its 200 day moving average is C$6.77.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- The move Washington made in 1934
- Iran Conflict Reveals Trump’s Most Powerful Weapon
- What happened to Blockbuster is about to happen to computers
- Central banks just did something they haven’t done since 1967
- Elon Musk’s $1 Quadrillion AI IPO
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
